What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Heart Failure Clinical Trials 2026: New Medications and Device Treatments

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Heart failure affects over 64 million people worldwide and remains a leading cause of hospitalization and death. In 2026, clinical research is focused on HFpEF (preserved ejection fraction) — the form of heart failure with the fewest approved treatments — as well as novel device-based therapies, anti-inflammatory approaches, and combination treatment strategies.

Understanding HFpEF vs. HFrEF

Heart failure comes in two main forms distinguished by ejection fraction (the percentage of blood pumped out with each heartbeat). HFrEF (reduced ejection fraction, EF <40%) has several evidence-based treatments — ACE inhibitors, beta-blockers, MRAs, SGLT2 inhibitors. HFpEF (preserved EF ≥50%) has far fewer proven therapies and represents the majority of new heart failure cases in aging populations.

SGLT2 inhibitors (empagliflozin, dapagliflozin) have recently shown mortality benefits in HFpEF, representing the first major breakthrough for this population. Current trials are building on this, investigating combination approaches and earlier intervention.

Key Trials in 2026

GLP-1 agonists for heart failure: Semaglutide showed significant improvements in symptoms and exercise capacity in HFpEF patients with obesity (STEP-HFpEF trial). Follow-up trials are testing GLP-1 agonists in broader HFpEF populations and combined with SGLT2 inhibitors.

Ziltivekimab (anti-inflammatory): This IL-6 ligand inhibitor targets cardiovascular inflammation. The ZEUS trial tested it in heart failure with elevated inflammatory markers, with results anticipated in 2026.

Aficamten (cardiac myosin inhibitor): Approved for obstructive hypertrophic cardiomyopathy (HCM) in 2024, aficamten is now being studied in broader heart failure populations including non-obstructive HCM.

Device-based therapies: The Alleviant System (interatrial shunt device) creates a small opening between heart chambers to reduce left atrial pressure. Phase 3 trials are ongoing. Cardiac contractility modulation (CCM) devices are also in trials for symptomatic HFrEF patients who are not candidates for ICD.

Gene therapy: Early-phase trials are testing AAV-delivered genetic constructs to restore calcium handling in heart failure cardiomyocytes — a fundamental mechanism of cardiac dysfunction.

Who Qualifies for Heart Failure Trials?

Eligibility typically requires a confirmed heart failure diagnosis with documentation of EF, NYHA functional class II–III (symptomatic but ambulatory), and stability on optimized background therapy. Many trials specify elevated NT-proBNP as an eligibility requirement — this biomarker confirms hemodynamic stress and enriches for a population likely to benefit.

Common exclusions include: recent hospitalization for acute decompensated heart failure (typically within 30–90 days), estimated GFR below threshold (often <20–30 mL/min), recent cardiac surgery or device implant, and significant valvular disease not addressed by surgery.

Finding a Heart Failure Trial

The Heart Failure Society of America (HFSA) and American College of Cardiology (ACC) maintain clinical trial resources. Most large academic medical centers and cardiology specialty clinics run industry-sponsored heart failure trials. Searching ClinicalMetric for "heart failure" filtered by "Recruiting" will show all currently open studies.